H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating on Aethlon Medical (AEMD – Research Report) today and set a price target of $9.00. The company’s shares opened today at $1.32.
According to TipRanks, Bernardino is a 5-star analyst with an average return of 25.2% and a 36.60% success rate. Bernardino covers the Healthcare sector, focusing on stocks such as Eledon Pharmaceuticals, Achieve Life Sciences, and Seres Therapeutics.
Aethlon Medical has an analyst consensus of Moderate Buy, with a price target consensus of $6.50, representing a 392.42% upside. In a report released yesterday, Maxim Group also maintained a Buy rating on the stock with a $4.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Based on Aethlon Medical’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $13.12 thousand and a GAAP net loss of $3.79 million. In comparison, last year the company earned a revenue of $34.23 thousand and had a GAAP net loss of $2.26 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aethlon Medical, Inc. is a therapeutic technology company, which focuses on addressing global health and biodefense needs. It develops Aethlon Hemopurifier, a medical device that targets the elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. The firm operates through two segments: Aethlon and ESI. The Aethlon segment involves in therapeutic business activities. The ESI segment consists of diagnostic business activities. The company was founded by James A. Joyce in May 1998 and is headquartered in San Diego, CA.
Read More on AEMD:
- Medicenna Announces Closing of Public Offering of Units Raising US$20 Million to Advance Pipeline
- InterCure to Release its Q2 2022 Results and Hold a Conference Call
- Pixelworks (PXLW) Receives a Buy from Needham
- H.C. Wainwright Sticks to Their Buy Rating for Aravive (ARAV)
- Early Warning Report Filed Pursuant to NI 62-103
